---
figid: PMC5736525__fonc-07-00312-g001
figlink: /pmc/articles/PMC5736525/figure/F1/
number: F1
caption: PIK3CB/p110β in glioblastoma. This figure illustrates a PIK3CB/p110β-dictated
  survival pathway in glioblastoma. Receptor tyrosine kinases (RTKs) or G protein-coupled
  receptors (GPCRs) selectively activates PIK3CB/p110β (but not PIK3CA/p110α or PIK3CD/p110δ),
  leading to production of phosphatidylinositol-3,4,5-triphosphate (PIP3) and subsequent
  phosphorylation of AKT. The activation of this signaling pathway promotes cancer
  cell survival while inhibiting cell death, the consequences of which are drug resistance
  and tumor recurrence. Hence, PIK3CB/p110β promotes glioblastoma disease progression
  and targeting PIK3CB/p110β using selective inhibitors represents a novel and effective
  approach to treating glioblastoma.
pmcid: PMC5736525
papertitle: The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic
  Subunits in Glioblastoma.
reftext: Kevin J. Pridham, et al. Front Oncol. 2017;7:312.
pmc_ranked_result_index: '735'
pathway_score: 0.9697112
filename: fonc-07-00312-g001.jpg
figtitle: PIK3CB/p110B in glioblastoma
year: '2017'
organisms:
- Mus musculus
- Diaporthe sclerotioides
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5736525__fonc-07-00312-g001.html
  '@type': Dataset
  description: PIK3CB/p110β in glioblastoma. This figure illustrates a PIK3CB/p110β-dictated
    survival pathway in glioblastoma. Receptor tyrosine kinases (RTKs) or G protein-coupled
    receptors (GPCRs) selectively activates PIK3CB/p110β (but not PIK3CA/p110α or
    PIK3CD/p110δ), leading to production of phosphatidylinositol-3,4,5-triphosphate
    (PIP3) and subsequent phosphorylation of AKT. The activation of this signaling
    pathway promotes cancer cell survival while inhibiting cell death, the consequences
    of which are drug resistance and tumor recurrence. Hence, PIK3CB/p110β promotes
    glioblastoma disease progression and targeting PIK3CB/p110β using selective inhibitors
    represents a novel and effective approach to treating glioblastoma.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT1
  - AKT2
  - AKT3
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
chemicals: []
diseases: []
figid_alias: PMC5736525__F1
redirect_from: /figures/PMC5736525__F1
figtype: Figure
---
